Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.67 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.56 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | BLK | P51451 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | STK3 | Q13188 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587569 | 0.89 | TGFBR1 (0.69) | ABCG2TGFBR1KDM1AROCK2ROCK1 | |
| SCHEMBL13154697 | 0.89 | TGFBR1 (0.71) | ABCG2TGFBR1ROCK2ROCK1PKN2 | |
| SCHEMBL29395013 | 0.89 | TGFBR1 (0.71) | ABCG2TGFBR1ROCK2ROCK1PKN2 | |
| SCHEMBL3578585 | 0.86 | TGFBR1 (0.65) | ABCG2TGFBR1ROCK2ROCK1PKN2 | |
| SCHEMBL3586914 | 0.86 | TGFBR1 (0.71) | ABCG2TGFBR1ROCK2ROCK1PKN2 | |
| SCHEMBL3589215 | 0.86 | TGFBR1 (0.65) | ABCG2TGFBR1KDM1AROCK2ROCK1 | |
| SCHEMBL1083782 | 0.84 | ROCK2 (0.66) | TGFBR1ROCK2ROCK1CLK2BLK | |
| SCHEMBL3582435 | 0.84 | KDM1A (0.67) | TGFBR1KDM1AROCK2 | |
| SCHEMBL3590103 | 0.84 | ABCG2 (0.67) | ABCG2TGFBR1KDM1AROCK2ROCK1 | |
| SCHEMBL3576082 | 0.83 | ROCK2 (0.71) | ABCG2TGFBR1ROCK2ROCK1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | claimed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | claimed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | claimed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | claimed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | disclosed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ABCG2 3107/4885TGFBR1 1599/4885KDM1A 1992/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | ABCG2 1193/4885TGFBR1 1926/4885KDM1A 1750/4885 |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | ABCG2 3107/4885TGFBR1 1599/4885KDM1A 1992/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | ABCG2 4736/4885TGFBR1 644/4885KDM1A 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.